Promoting Patient Interests in Implementing the Federal Right to Try Act-Reference-Cited by-同舟云学术

Promoting Patient Interests in Implementing the Federal Right to Try Act

Published:2018-09-04 Issue:9 Volume:320 Page:869
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Lynch Holly Fernandez¹,Zettler Patricia J.²,Sarpatwari Ameet³

Affiliation:

1. Department of Medical Ethics and Health Policy, Perelman School of Medicine, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia

2. Center for Law, Health, and Society, Georgia State University College of Law, Atlanta

3. Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Reference9 articles.

1. Ten-year experience for the Center for Drug Evaluation and Research, part 2: FDA’s role in ensuring patient safety.;Jarow;Ther Innov Regul Sci,2017

2. How often are drugs made available under the Food and Drug Administration’s expanded access process approved?;McKee;J Clin Pharmacol,2017

3. SwetlitzI. Physicians, ethicists urge Congress not to pass ‘right-to-try’ legislation. STAT News. https://www.statnews.com/2018/02/01/physicians-ethicists-congress-right-to-try/. Published February 1, 2018. Accessed June 12, 2018.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies;Cytotherapy;2023-07

2. Multiple deadlocks in the development of nonprofit drugs;Drug Discovery Today;2022-09

3. Prescribing unproven cancer drugs: physician perspectives on expanded access and right to try;Journal of Law and the Biosciences;2022-07-01

4. Aspiring to Reasonableness in Accelerated Approval: Anticipating and Avoiding the Next Aducanumab;Drugs & Aging;2022-06

5. Reviewing fair subject selection considerations for the unique case of post sequelae COVID-19 translational studies;Journal of Clinical and Translational Science;2022